National Breast and Cervical Cancer Early Detection Program (NBCCEDP) Monitoring Activities
Revision of a currently approved collection
No
Regular
11/18/2021
table that charts list comparision
Requested
Previously Approved
36 Months From Approved
11/30/2021
1,400
910
1,228
764
38,976
38,976
CDC is required to monitor and evaluate processes and outcomes for the NBCCEDP. Recipients are required to report information to CDC to support these efforts. Based on the redesigned NBCCEDP under DP22-2202, CDC developed a logic model to illustrate the strategies and expected outcomes associated with the NBCCEDP over time (Attachment 3 â DP22-2202 NBCCEDP Logic Model). In contrast to DP17-1701, DP22-2202 has a stronger focus on selecting and engaging partners to support NBCCEDP implementation, including serving populations disproportionately burdened by breast and/or cervical cancer and tracking them through screening completion. As illustrated in the logic model, CDC anticipates that recipientsâ implementation of the five strategies and activities described will result in several desired short-, intermediate-, and long-term outcomes, including increased breast and cervical screening rates. The logic model guided development of CDCâs NBCCEDP monitoring and evaluation plan, which includes evaluation questions and sub-questions that map to the proposed information collections (Attachment 4 â NBCCEDP Evaluation Question Matrix) to be addressed through systematic monitoring and evaluation of these key strategies and the primary outcome of screening rate changes over time. In 2022, CDC will issue a new Notice of Funding Opportunity (DP22-2202) to continue this mission with a stronger focus on collaborating with other public health programs and community-based organizations to serve populations disproportionately burdened by breast and/or cervical cancer. Based on data collection conducted throughout DP17-1701 and consistent with programmatic changes, the information collection plan has also been revised to update existing and add new data collection instruments and integrate the previously approved MDEs into this single approval package to increase efficiency. DP22-2202 is expected to fund the same number of recipients (N=70).
US Code:
42 USC 300k
Name of Law: Breast and Cervical Cancer Mortality Prevention Act of 1990
PL:
Pub.L. 101 - 354 2
Name of Law: Breast and Cervical Cancer Prevention and Treatment Act of 2000
These revisions were made to improve data quality. Because revisions increased the number of questions in the annual survey, burden hours increased from 56 to 65 burden hours. Revisions to the clinic-level data collection did not result in increased burden; therefore, the estimated burden remains the same. The QPU is new and involves four annual submissions for all 70 recipients for a net increase of 104 estimated burden hours. The service delivery projection worksheet is also new and involves an annual submission for all 70 recipients for a net increase of 34 estimated burden hours. There were no changes to the MDEs; therefore, the estimated burden remains the same.
On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control number;
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.
Form 0920-1046 Minimum Data Elements (MDE) Data Definition Table
0920-1046_PIA final.pdf
Att 10 - Institutional Review Board Approval.docx
Minimum Data Elements (MDE) Data Definition Table